Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Dose-Dense Chemotherapy and Erlotinib in Advanced NSCLC
NCT01557959Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2007
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Started Jul 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01557959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01557959.